Revvity, Inc. RVTY

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Con 6 acciones de RVTY (USD 953,35) habrías recibido USD 1,68 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?

  Revvity (RVTY), a maker of scientific instruments, has been upgraded to Zacks Rank #2 (Buy) due to rising earnings estimate revisions over the past three months. The upgrade reflects positive momentum in the company's earnings outlook, which historically correlates with near-term stock price increases. The company is expected to earn $5.36 per share for fiscal year 2026.

  

• GlobeNewswire Inc. 30 sept

  North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity

  The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.

  

• Zacks Investment Research 29 sept

  Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

  Revvity (RVTY) is rated a Hold with strong growth potential across diagnostics, life sciences, and scientific informatics. The company benefits from AI-driven demand, the planned Human Cell Design acquisition, and solid diagnostics growth (11% organic revenue increase in Q2). However, challenges include China divestiture uncertainty, uneven academic funding, and margin pressure from non-recurring tariff benefits. The stock has outperformed the broader market with a 56.1% year-to-date gain.

  

• GlobeNewswire Inc. 22 sept

  Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight

  The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.

  

• Zacks Investment Research 16 sept

  Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

  Revvity shares surged 9.1% to $140.19 following upbeat commentary on AI-driven demand for research tools, improved order backlog, and a planned acquisition of Human Cell Design. The company expects quarterly EPS of $1.28 (+8.5% YoY) and revenues of $702.56M (+0.5% YoY). However, consensus EPS estimates have been marginally revised lower over the past 30 days, which could limit further price appreciation.